Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
exendin(4-39)
- Development stage
- Preclinical
- Lead developer
- Amylyx Pharmaceuticals
- Modality
- Peptides
- Administration
- Subcutaneous
01
Overview
exendin(4-39) is a synthetic peptide and an N-terminally truncated derivative of exendin-4 that acts as a glucagon-like peptide-1 (GLP-1) receptor antagonist. It is covered under a patent family originally assigned to Eiger BioPharmaceuticals (and subsequently acquired by Amylyx Pharmaceuticals) for the treatment of hyperinsulinemic hypoglycemia, including post-bariatric hypoglycemia and congenital hyperinsulinism. By removing the first three amino acids of the full-length exendin-4 agonist, exendin(4-39) retains antagonist activity at the GLP-1 receptor, similar to the more widely studied antagonist exendin(9-39) (avexitide).
- Other names
- exendin-4(4-39)
02
Targets
Beyond the preview
Go deeper on exendin(4-39).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on exendin(4-39).